Cell 168, 960976
O., & Uspenskaya, M
We only recommend topical glutathione, since it is the safest form and widely available
Water, Niacinamide, Dipropylene Glycol, Glycerin, Propanediol, Butylene Glycol, Hydroxyethyl Urea, Diethoxyethyl Succinate, Hydroxyacetophenone, Caprylyl Glycol, Polyglyceryl-10 Laurate, Betaine, Citric Acid, Panthenol, Ethylhexylglycerin, Gluconolactone, Sodium Polyacrylate, Disodium EDTA, Ammonium Acryloyldimethyltaurate/VP Copolymer, Sodium Citrate, Maltodextrin, 1,2-Hexanediol, Gardenia Florida Fruit Extract, Dipotassium Glycyrrhizate, Sodium Hyaluronate, Ascorbic Acid, Pantolactone, Tocopherol, Capryloyl Salicylic Acid, Tranexamic Acid, Tremella Fuciformis (Mushroom) Extract, Caprylic/Capric Triglyceride, Ascorbyl Glucoside, Ubiquinone, Hydrogenated Lecithin, Magnesium Chloride, Alcohol, Glutathione, Polysorbate 80, Calcium Gluconate, Pyridoxine HCl, BHT, Yeast Extract, Cyanocobalamin
GLP-1R agonists have been approved for the treatment of T2DM since 2005, but it was only with the approval of tirzepatide (a dual GLP-1R/GIPR agonist) in 2022 that a drug acting on GIPR was used clinically (Le Roux et al., 2023)
